Page 5 - Les Meilleurs Chimiothérapie pour votre Chimiothérapie - TOP 156 des médecins

Forbes a désigné le Dr Tabernero comme l'un des 5 leaders les plus influents d'Espagne dans le domaine du cancer. Ancien président de la Société Européenne d'Oncologie Médicale.

• Directeur de l'Institut d'Oncologie Vall d’Hebrón
• Spécialisé dans les thérapies ciblées moléculaires et les traitements personnalisés du cancer
• Auteur de plus de 70 articles sur les traitements innovants contre le cancer
• Mène des essais cliniques pour de nouvelles thérapies contre le cancer du côlon

Le Prof. Assoc. Atakan Topcu est spécialisé dans les tumeurs solides et les affections liées au cancer, et apporte une expertise approfondie dans les thérapies ciblées et l'immunothérapie.

• A publié plus de 50 articles scientifiques en oncologie
• Membre de l'ESMO et de la Société Turque d'Oncologie Médicale
• Se concentre sur l'oncologie gériatrique et la malnutrition liée au cancer
• Formation de surspécialisation (Fellowship) en oncologie médicale à l'Université Bezmialem Vakıf

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Le Dr Alemdar est spécialisé en oncologie médicale avec une formation approfondie à l'Université d'Akdeniz – une institution de premier plan en Turquie.

• Certifié en oncologie médicale depuis 2018
• Plus de 15 ans d'expérience en médecine interne et en oncologie
• Travaille au complexe hospitalier Medical Park Antalya
• Membre de l'Association médicale turque

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Directeur clinique d'une unité multidisciplinaire du sein avec 322 publications évaluées par des pairs – Le Dr Kuemmel dirige la recherche sur le cancer du sein aux Kliniken Essen-Mitte.

• Membre du conseil d'administration de l'AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)
• Membre de la faculté de l'ESMO pour le cancer du sein
• PI mondial et responsable de 27 investigations et essais cliniques
• Membre de plusieurs sociétés d'oncologie prestigieuses, dont l'ESMO et l'ASCO

Le professeur agrégé Muhammed Mustafa Atci dirige le programme d'oncologie médicale à l'hôpital universitaire İstinye Liv Topkapı, avec des recherches approfondies sur les résultats de la chimiothérapie.

• Spécialisé en oncologie médicale, axé sur les protocoles de chimiothérapie
• A publié de nombreuses études sur l'efficacité de la chimiothérapie dans des revues à comité de lecture
• Membre de l'American Society of Clinical Oncology (ASCO)
• Coordinateur de l'éducation pour la sous-branche d'oncologie médicale

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Le Dr Prat dirige SOLTI en tant que président, concevant des essais cliniques pour les traitements du cancer du sein. Ses recherches portent sur l'expression génique et les sous-types moléculaires.

• Chef de la génomique translationnelle et des thérapies ciblées (Targeted Therapeutics) à l'IDIBAPS
• Co-fondateur de Reveal Genomics, détenteur de trois brevets
• Plus de 160 publications avec un indice H de 51
• Formation post-doctorale (Fellowship) en oncologie médicale au Vall d´Hebron Institute of Oncology
• Professeur en voie de titularisation (Tenure-Track) à l'Université de Barcelone

Le Dr Graus est un expert de premier plan dans le domaine des syndromes neurologiques paranéoplasiques, ayant défini les premiers critères diagnostiques stricts pour ces affections.

• Plus de 40 ans d'expérience en neuro-oncologie
• Ancien Chef de Neurologie à l'Hospital Clinic de Barcelone
• Fondateur et ancien président de l'Association européenne de neuro-oncologie
• Spécialisé dans les neurotoxicités découlant des traitements contre le cancer
• Doctorat honorifique de l'Université de Lyon

Spécialisé(e) en oncologie gynécologique et en chimiothérapie au Samsung Medical Center.

• Expertise ciblée dans les cancers gynécologiques et les traitements de chimiothérapie
• Exerce au Samsung Medical Center, un établissement de santé de premier plan
• Oncogynécologue avec une solide expérience dans la prise en charge des cancers féminins

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Spécialiste israélien de premier plan en immunothérapie du cancer du poumon – le Prof. Peled dirige l'Unité des cancers thoraciques au Centre de cancérologie Davidoff.

• Formation de fellowship en cancer du poumon à l'Université du Colorado à Denver
• Récipiendaire du prix MERIT de l'American Society of Clinical Oncology (ASCO)
• Préside le Comité de détection précoce et de prévention de l'IASLC
• Spécialisé en médecine personnalisée et en immuno-oncologie pour le cancer du poumon

Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.

She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.

She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.